Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events

References

• Millennium Development Goals for Health: What Will It Take to Accelerate Progress? Wagstaff A, Claeson M, Hecht RM, Gottret P, Fang Q. http://www.ncbi.nlm.nih.gov/pubmed?term=%22Jamison%20DT%22%5BEditor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract Disease Control Priorities in Developing Countries. 2nd edition. Washington (DC): World Bank; 2006. Chapter 9.
   Google Scholar
• Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, Schmidt C, et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 2006; 24:417 - 25; http://dx.doi.org/10.1016/j.vaccine.2005.08.041; PMID: 16176847
   PubMed Web of Science ®Google Scholar
• Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 2007; 25:2120 - 7; http://dx.doi.org/10.1016/j.vaccine.2006.11.016; PMID: 17250931
   PubMed Web of Science ®Google Scholar
• Guimarães-Walker A, Mackie N, McCormack S, Hanke T, Schmidt C, Gilmour J, et al, IAVI-006 Study Group. Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine 2008; 26:6671 - 7; http://dx.doi.org/10.1016/j.vaccine.2008.09.016; PMID: 18812202
   PubMed Web of Science ®Google Scholar
• Jaoko W, Nakwagala FN, Anzala O, Manyonyi GO, Birungi J, Nanvubya A, et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 2008; 26:2788 - 95; http://dx.doi.org/10.1016/j.vaccine.2008.02.071; PMID: 18440674
   PubMed Web of Science ®Google Scholar
• Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, Mahmoud A, et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 2006; 80:4717 - 28; http://dx.doi.org/10.1128/JVI.80.10.4717-4728.2006; PMID: 16641265
   PubMed Web of Science ®Google Scholar
• Mehendale S, van Lunzen J, Clumeck N, Rockstroh J, Vets E, Johnson PR, et al. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS Res Hum Retroviruses 2008; 24:873 - 80; http://dx.doi.org/10.1089/aid.2007.0292; PMID: 18544020
   PubMed Web of Science ®Google Scholar
• Ramanathan VD, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan PR, Solomon S, et al. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses 2009; 25:1107 - 16; http://dx.doi.org/10.1089/aid.2009.0096; PMID: 19943789
   PubMed Web of Science ®Google Scholar
• Vasan S, Schlesinger SJ, Chen Z, Hurley A, Lombardo A, Than S, et al. Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B’/C candidate vaccine. PLoS One 2010; 5:e8816; http://dx.doi.org/10.1371/journal.pone.0008816; PMID: 20111599
   PubMed Web of Science ®Google Scholar
• Vasan S, Schlesinger SJ, Huang Y, Hurley A, Lombardo A, Chen Z, et al. Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B’ HIV-1 candidate vaccine. PLoS One 2010; 5:e8617; http://dx.doi.org/10.1371/journal.pone.0008617; PMID: 20111582
   PubMed Web of Science ®Google Scholar
• Vardas E, Kaleebu P, Bekker LG, Hoosen A, Chomba E, Johnson PR, et al. A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV-1 Vaccine Based on Adeno-Associated Virus. AIDS RHR 2010; 26:933 - 42; PMID: 20666584
   PubMed Web of Science ®Google Scholar
• Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, et al. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 2010; 5:e12873; http://dx.doi.org/10.1371/journal.pone.0012873; PMID: 20877623
   PubMed Web of Science ®Google Scholar
• Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011; 6:e19252; http://dx.doi.org/10.1371/journal.pone.0019252; PMID: 21603651
   PubMed Web of Science ®Google Scholar
• Karita E, Ketter N, Price MA, Kayitenkore K, Kaleebu P, Nanvubya A, et al. CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS One 2009; 4:e4401; http://dx.doi.org/10.1371/journal.pone.0004401; PMID: 19197365
   PubMed Web of Science ®Google Scholar
• Lugada ES, Mermin J, Kaharuza F, Ulvestad E, Were W, Langeland N, et al. Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clin Diagn Lab Immunol 2004; 11:29 - 34; PMID: 14715541
   PubMedGoogle Scholar
• Van den Broeck J, Robinson AKL. Towards research equity -- challenges of safety monitoring during clinical trials in resource-limited settings. West Indian Med J 2007; 56:163 - 5; http://dx.doi.org/10.1590/S0043-31442007000200011; PMID: 17910148
   PubMed Web of Science ®Google Scholar
• DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. . www.rsc-tech.com
   Google Scholar